Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533413 | 0.91 | CASR (0.38) | ALDH1A1MAPTNPSR1HTTSLC6A2 | |
| SCHEMBL2532967 | 0.89 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EHTTMEN1 | |
| SCHEMBL2576665 | 0.86 | ALDH1A1 (0.39) | ALDH1A1MAPTNPSR1KDM4EHTT | |
| SCHEMBL2529286 | 0.86 | ALDH1A1 (0.41) | ALDH1A1MAPTNPSR1KDM4EHTT | |
| SCHEMBL2533681 | 0.85 | ALDH1A1 (0.42) | ALDH1A1MAPTNPSR1KDM4ETSHR | |
| SCHEMBL15509520 | 0.85 | KMT2A (0.36) | ALDH1A1HTTMEN1KMT2A | |
| SCHEMBL2531852 | 0.83 | ALDH1A1 (0.39) | ALDH1A1MAPTNPSR1KDM4EHTT | |
| SCHEMBL2529499 | 0.80 | CYP26A1 (0.36) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL2537624 | 0.80 | LMNA (0.46) | ALDH1A1MAPTKDM4EHTTMEN1 | |
| SCHEMBL2589366 | 0.78 | SMN1; SMN2 (0.38) | ALDH1A1MAPTKDM4EHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2558449-B1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-8586747-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2558449-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-20 | — | — | EP | disclosed |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | Hoffmann-La Roche Inc (US) | 2013-01-24 | — | — | US | disclosed |
| US-8344137-B2 | 3,3-dimethyl tetrahydroquinoline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011128251-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | HUA MEDICINE (KY) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257151-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | ALDH1A1 552/4885MAPT 3094/4885NPSR1 853/4885 |
| US-20130023518-A1 | NOVEL 3,3-DIMETHYL TETRAHYDROQUINOLINE DERIVATIVES | QDPR, PRMT3, PRMT1 | ALDH1A1 552/4885MAPT 3094/4885NPSR1 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.